(VIANEWS) – Eli Lilly and Company (LLY), Martin Marietta Materials (MLM), Dominion Resources (D) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Eli Lilly and Company (LLY)
27.9% sales growth and 65.6% return on equity
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Earnings Per Share
As for profitability, Eli Lilly and Company has a trailing twelve months EPS of $5.34.
PE Ratio
Eli Lilly and Company has a trailing twelve months price to earnings ratio of 107. Meaning, the purchaser of the share is investing $107 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 65.6%.
Yearly Top and Bottom Value
Eli Lilly and Company’s stock is valued at $571.38 at 01:22 EST, under its 52-week high of $629.97 and way higher than its 52-week low of $309.20.
Sales Growth
Eli Lilly and Company’s sales growth is 29% for the current quarter and 27.9% for the next.
2. Martin Marietta Materials (MLM)
19.9% sales growth and 13.54% return on equity
Martin Marietta Materials, Inc., a natural resource-based building materials company, supplies aggregates and heavy-side building materials to the construction industry in the United States and internationally. It offers crushed stone, sand, and gravel products; ready mixed concrete and asphalt; paving products and services; and Portland and specialty cement for use in the infrastructure projects, and nonresidential and residential construction markets, as well as in the railroad, agricultural, utility, and environmental industries. The company also produces magnesia-based chemicals products; dolomitic lime primarily to customers for steel production and soil stabilization; and cement treated materials. Its chemical products are used in flame retardants, wastewater treatment, pulp and paper production, and other environmental applications. Martin Marietta Materials, Inc. was founded in 1939 and is headquartered in Raleigh, North Carolina.
Earnings Per Share
As for profitability, Martin Marietta Materials has a trailing twelve months EPS of $17.72.
PE Ratio
Martin Marietta Materials has a trailing twelve months price to earnings ratio of 25.04. Meaning, the purchaser of the share is investing $25.04 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.54%.
Sales Growth
Martin Marietta Materials’s sales growth is 19% for the ongoing quarter and 19.9% for the next.
Previous days news about Martin Marietta Materials(MLM)
- According to Zacks on Saturday, 4 November, "Among the Zacks Construction sector, Martin Marietta Materials (MLM Quick QuoteMLM – Free Report) also posted strong Q3 earnings on Wednesday with its Zacks Building Products-Concrete and Aggregate Industry in the top 38% of all Zacks industries."
3. Dominion Resources (D)
17.2% sales growth and 8.23% return on equity
Dominion Energy, Inc. produces and distributes energy in the United States. It operates through four segments: Dominion Energy Virginia, Gas Distribution, Dominion Energy South Carolina, and Contracted Assets. The Dominion Energy Virginia segment generates, transmits, and distributes regulated electricity to approximately 2.7 million residential, commercial, industrial, and governmental customers in Virginia and North Carolina. The Gas Distribution segment is involved in the regulated natural gas sales, transportation, gathering, storage, and distribution operations in Ohio, North Carolina, Utah, southwestern Wyoming, and southeastern Idaho that serve approximately 3.0 million residential, commercial and industrial customers. It also has nonregulated renewable natural gas facilities in operation. The Dominion Energy South Carolina segment generates, transmits, and distributes electricity to approximately 782,000 customers in the central, southern, and southwestern portions of South Carolina; and distributes natural gas to approximately 435,000 residential, commercial, and industrial customers in South Carolina. The Contracted Assets segment is involved in the nonregulated long-term contracted renewable electric generation and solar generation facility development operations; and gas transportation, LNG import, and storage operations, as well as in the liquefaction facility. As of December 31, 2022, the company's portfolio of assets included approximately 31.0 gigawatt of electric generating capacity; 10,600 miles of electric transmission lines; 78,500 miles of electric distribution lines; and 93,500 miles of gas distribution mains and related service facilities. The company was formerly known as Dominion Resources, Inc. Dominion Energy, Inc. was incorporated in 1983 and is headquartered in Richmond, Virginia.
Earnings Per Share
As for profitability, Dominion Resources has a trailing twelve months EPS of $2.7.
PE Ratio
Dominion Resources has a trailing twelve months price to earnings ratio of 16.28. Meaning, the purchaser of the share is investing $16.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.23%.
Moving Average
Dominion Resources’s value is below its 50-day moving average of $45.08 and way under its 200-day moving average of $52.59.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 28.8% and a negative 12.3%, respectively.
4. Zynex (ZYXI)
17.2% sales growth and 26.28% return on equity
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.
Earnings Per Share
As for profitability, Zynex has a trailing twelve months EPS of $0.45.
PE Ratio
Zynex has a trailing twelve months price to earnings ratio of 15.78. Meaning, the purchaser of the share is investing $15.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.28%.
Volume
Today’s last reported volume for Zynex is 191458 which is 54.13% below its average volume of 417431.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Zynex’s EBITDA is 64.85.
Moving Average
Zynex’s value is way below its 50-day moving average of $7.90 and way under its 200-day moving average of $10.25.
Yearly Top and Bottom Value
Zynex’s stock is valued at $7.10 at 01:22 EST, way below its 52-week high of $17.25 and higher than its 52-week low of $6.88.
5. CME Group (CME)
9.8% sales growth and 10.81% return on equity
CME Group Inc., together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services. The company also provides clearing house services, including clearing, settling, and guaranteeing futures and options contracts, and cleared swaps products traded through its exchanges; and trade processing and risk mitigation services. In addition, the company offers a range of market data services, including real-time and historical data services. It serves professional traders, financial institutions, institutional and individual investors, corporations, manufacturers, producers, governments, and central banks. The company was formerly known as Chicago Mercantile Exchange Holdings Inc. and changed its name to CME Group Inc. in July 2007. CME Group Inc. was founded in 1898 and is headquartered in Chicago, Illinois.
Earnings Per Share
As for profitability, CME Group has a trailing twelve months EPS of $8.37.
PE Ratio
CME Group has a trailing twelve months price to earnings ratio of 24.78. Meaning, the purchaser of the share is investing $24.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.81%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 12.1% and 12%, respectively.
Sales Growth
CME Group’s sales growth is 9.9% for the present quarter and 9.8% for the next.
Yearly Top and Bottom Value
CME Group’s stock is valued at $207.39 at 01:22 EST, under its 52-week high of $221.76 and way above its 52-week low of $166.55.
Revenue Growth
Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 5.34B for the twelve trailing months.
Previous days news about CME Group(CME)
- According to FXStreet on Wednesday, 1 November, "According to the CME Group FedWatch Tool, markets are pricing in a 20% probability that the US central bank will hike the policy rate in December."
- According to CNBC on Wednesday, 1 November, "Market pricing indicates the first cut could come around June 2024, according to CME Group data."
6. Ingredion Incorporated (INGR)
5.1% sales growth and 17.47% return on equity
Ingredion Incorporated, together with its subsidiaries, produces and sells starches and sweeteners for various industries. It operates through four segments: North America; South America; Asia Pacific; and Europe, Middle East, and Africa. The company offers sweetener products comprising glucose syrups, high maltose syrups, high fructose corn syrups, caramel colors, dextrose, polyols, maltodextrins, glucose and syrup solids, as well as food-grade and industrial starches, biomaterials, and nutrition ingredients. It also provides animal feed products; edible corn oil; refined corn oil to packers of cooking oil and to producers of margarine, salad dressings, shortening, mayonnaise, and other foods; and corn gluten feed used as protein feed for chickens, pet food, and aquaculture. The company's products are derived primarily from processing corn and other starch-based materials, such as tapioca, potato, and rice. It serves food, beverage, paper and corrugating products, brewing, pharmaceutical, textile, and personal care industries, as well as animal feed markets. The company was formerly known as Corn Products International, Inc. and changed its name to Ingredion Incorporated in June 2012. Ingredion Incorporated was founded in 1906 and is headquartered in Westchester, Illinois.
Earnings Per Share
As for profitability, Ingredion Incorporated has a trailing twelve months EPS of $8.57.
PE Ratio
Ingredion Incorporated has a trailing twelve months price to earnings ratio of 10.81. Meaning, the purchaser of the share is investing $10.81 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.47%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.2%, now sitting on 8.22B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Ingredion Incorporated’s EBITDA is 31.
Yearly Top and Bottom Value
Ingredion Incorporated’s stock is valued at $92.67 at 01:22 EST, way under its 52-week high of $113.46 and higher than its 52-week low of $87.40.
